Gangamani S Beligere

This inventor holds 6 USPTO granted patents and 5 published patent applications, plus 2 CIPO patents and 2 EPO patents. Top assignees: Abbott Laboratories Corporation, Abbott Japan LLC, Abbvie Deutschland Gmbh and Co Kg. Active years: 2011-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gangamani S Beligere. Retrieved from https://idiyas.com/inventor/gangamani-s-beligere

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 6 (Patent Applications = 5)

% Patents Active = 66.7

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 2 (Patent Applications = 6)

Average Co-Inventor Count = 4.7

ph-index = 3

Forward Citations = 20(Granted Patents)

Location History:

Grayslake, IL (US) (2011 - 2017)
Abbott Park, IL (US) (2021)

Company Filing History:

5 out of 4,190

Abbott Laboratories Corporation

Abbvie Deutschland Gmbh and Co Kg

where one patent can have more than one assignee

Years Active: 2011-2024

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12123883 - Methods for measuring ubiquitin carboxy—terminal hydrolase L1 levels in blood (2024-10-22),

2. 11169159 - Methods for measuring ubiquitin carboxy-terminal hydrolase L1 levels in blood (2021-11-09),

3. 9636398 - Composition and method for the diagnosis and treatment of iron-related disorders (2017-05-02),

4. 9120862 - Antibodies relating to PIVKA-II and uses thereof (2015-09-01),

5. 8283162 - Antibodies relating to PIVKAII and uses thereof (2012-10-09),

6. 8013112 - Compositions comprising human brain natriuretic peptide (BNP) fragments (2011-09-06),

Title: The Innovative Mind of Gangamani S. Beligere

Introduction

Gangamani S. Beligere is a notable inventor located in Grayslake, IL. With a total of 6 patents to his name, his contributions to the field of biomedical research are significant. His inventions primarily focus on advancing methods for health diagnostics, particularly in relation to traumatic brain injuries.

Latest Patents

One of Gangamani S. Beligere's latest patents encompasses methods for measuring ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) levels in blood. These improved methods are designed for processing, measuring, and detecting levels of UCH-L1 in blood samples taken from human subjects within approximately 8 hours after obtaining the sample. UCH-L1 is recognized as an early biomarker for traumatic brain injury (TBI), thus enhancing the potential for timely diagnosis and evaluation of individuals who have sustained head injuries.

Career Highlights

Throughout his career, Gangamani has worked with prominent companies such as Abbott Laboratories Corporation and AbbVie Deutschland GmbH & Co. KG. His experience in these leading research institutions has allowed him to contribute significantly to innovative healthcare solutions.

Collaborations

Collaboration has played a key role in Gangamani’s career. Notable coworkers, including Toru Yoshimura and Barry Lee Dowell, have contributed to his research endeavors, fostering an environment of teamwork and shared innovation.

Conclusion

Gangamani S. Beligere’s innovative work in the area of UCH-L1 levels measurement has the potential to greatly influence the diagnosis and treatment of traumatic brain injuries. His dedication to advancing biomedical research will undoubtedly continue to impact the healthcare industry positively. Through his patents and collaborations, he exemplifies the spirit of innovation needed in today’s medical landscape.

Profile summary based on public USPTO records.